 |
|
|
 
|
|
|
Following Practice Guidelines is Critical
ESC/ACC Guidelines
Advances in clinical practice, healthcare delivery systems, epidemiological studies and clinical trials all require a more precise definition of MI.1
Criteria for Acute Evolving or Recent MI1
Either one of the following criteria satisfies the diagnosis of an acute, evolving or recent MI:
|
Recent consensus documents by the European Society of Cardiology (ESC) and the American College of Cardiology (ACC)1 make specific recommendations on the use of biomarkers for the detection of myocardial infarction.
| |
|
Sensitive biochemical markers enable the detection of myocardial necrosis too small to be associated with QRS abnormalities1
|
| |
|
The use of cardiac markers has become the standard to risk-stratify chest pain patients1
|
|
" Testing for multiple markers of myocardial necrosis, in a manner that emphasizes temporal patterns, could enhance the prompt recognition of high-risk patients and improve risk stratification across a range of patients with chest pain syndromes. This strategy, used at the point-of-care, making test results more readily available to treating physicians, could improve the efficiency of chest pain management and treatment and triage decisions."
L.K. Newby, A.B. Storrow, W.B. Gibler, et al. Circulation. 2001.2
" Each of these clinical groups [ESC/ACC/AHA] along with the laboratory community has independently reached the conclusion that cardiac troponin is the best marker for diagnosis, risk stratification and guidance of therapy in ACS."
F.S. Apple and A.H.B. Wu. Clinical Chemistry. 2001.3
|
|
View more about the latest practice guidelines:
ESC/ACC
ACC/AHA
NACB
|
| |
|
|
 |
 |
 |
|
|
